Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version

Eun-Young Bae, Jihyung Hong, SeungJin Bae, Seokyung Hahn, Hyonggin An, Eun-joo Hwang, Seung-min Lee and Tae-jin Lee ()
Additional contact information
Eun-Young Bae: Gyeongsang National University
Jihyung Hong: Gachon University
SeungJin Bae: Ewha Womans University
Seokyung Hahn: Seoul National University
Hyonggin An: Korea University
Eun-joo Hwang: Health Insurance Review and Assessment Service
Seung-min Lee: Health Insurance Review and Assessment Service
Tae-jin Lee: Seoul National University

Applied Health Economics and Health Policy, 2022, vol. 20, issue 4, No 3, 467-477

Abstract: Abstract The first version of the pharmacoeconomic (PE) guidelines was published in South Korea in 2006. Despite its first revision in 2011, there were still ambiguities in its interpretation. Moreover, methodologies for estimating effectiveness and costs have also evolved since then. Under these circumstances, the Health Insurance Review and Assessment Service published the third version in January 2021. This article reviews the revision process and major changes made in the new edition of the PE guidelines. The revision was processed through reviews of the previous 50 PE submissions, international guidelines, academic literature, and surveys and advisory meetings to obtain stakeholders’ opinions. The analysis perspective has changed from a limited societal perspective to a healthcare system perspective. In addition to the drug with the highest market share, drugs used in clinical trials can be selected as comparators under certain conditions. The discount rate decreased from 5% to 4.5%. Furthermore, the revised guidelines provide more detailed and specific instructions for items including non-inferiority margin, extrapolation, utility elicitation, and uncertainty. Treatment switch and co-dependent technology guidelines are newly included; the budget impact analysis guideline is deleted. Through this revision, transparency and consistency of decision-making is expected to improve.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://link.springer.com/10.1007/s40258-022-00721-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:20:y:2022:i:4:d:10.1007_s40258-022-00721-4

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-022-00721-4

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().